Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines gibt die Zulassung durch die US-amerikanische FDA für eine auf TEVIMBRA basierende Therapie zur Erstlinienbehandlung von HER2-positiver GEA bekannt

Wednesday, August 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines has announced that the FDA has approved a supplemental biologics license application for TEVIMBRA (Tislelizumab) in combination with ZIIHERA (Zanidatamab) and chemotherapy. This therapy is intended for first-line treatment of adult patients with inoperable, locally advanced, or metastatic HER2-positive gastric cancer. This approval represents a significant advancement in treatment options for this patient population.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA approval for TEVIMBRA-based therapy is a significant milestone.
  • The therapy targets HER2-positive gastric cancer, addressing a critical need.
  • Combination treatment may enhance patient outcomes in advanced cases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 2 · Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma

Full Press Release Details

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den ergänzenden Antrag auf Zulassung eines biologischen Präparats (sBLA) für TEVIMBRA® (Tislelizumab) in Kombination mit ZIIHERA® (Zanidatamab) und einer Chemotherapie zur Erstlinienbehandlung erwachsener Patienten mit inoperablem, lokal fortgeschrittenem oder metastasier

Frequently Asked Questions

What therapy did BeOne Medicines receive FDA approval for?

BeOne Medicines received FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy.

What type of cancer does the approved therapy target?

The therapy targets HER2-positive gastric cancer.

What is the intended use of the approved therapy?

It is intended for first-line treatment of advanced gastric cancer.

Who are the patients eligible for this therapy?

The therapy is for adult patients with inoperable or metastatic HER2-positive gastric cancer.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines TEVIMBRA HER2-positive FDA approval gastric cancer
Last updated: Aug 26, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TislelizumabPhase 2
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →